Biotech Values

[DewDiligence]

Norbert [Bischofberger] would better serve GILD's shareholders if he withheld comment until after he signs a deal.

Why do you say that? Bischofberger was replying to an analyst’s CC question about HCV in-licensing; he was not making an unsolicited tout about dealmaking prowess as some HCV companies (including one that you follow closely) have been known to do :- )